INHIBITOR Therapeutics, Inc. is a publicly traded pharmaceutical company (OTCQB:INTI) focused on developing and commercializing innovative therapies for patients with cancer and non-cancerous proliferation disorders.

SUBA-Itraconazole, the company’s lead product candidate, is a patented, oral formulation of the currently FDA approved and marketed, well-understood, anti-fungal drug, itraconazole, which, when studied to treat patients with cancer, has demonstrated activity against multiple tumor types. INHIBITOR is developing SUBA-Itraconazole for late-stage, metastatic castrate-resistant prostate cancer (mCRPC) and late-stage non-squamous non-small cell lung cancer (NSCLC). INHIBITOR is the exclusive U.S. licensee for SUBA-Itraconazole for the treatment of certain cancers and non-cancerous proliferation disorders.

INHIBITOR’s lead programs are clinically de-risked due to itraconazole’s prior FDA approval (505(b)(2) pathway), with proven bioavailability, safety and anti-tumor efficacy previously demonstrated in an INHIBITOR clinical trial testing SUBA-Itraconazole in 38 patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS). Solid clinical execution was demonstrated with the completion of a Phase 2b trial in BCCNS, confirming a low toxicity safety profile when compared to published data for other oncology drugs that inhibit the same pathway as a treatment for basal cell carcinoma (BCC) lesions.

Biotechnology

Health Care

Pharmaceutical

Therapeutics

INHIBITOR Therapeutics, Inc.

INHIBITOR Therapeutics, Inc.'s headquarters in Tampa, United States

INHIBITOR Therapeutics, Inc.

Org chart

Teams

Offices

Similar companies